10x Genomics Stock News

10x Genomics Inc. (NASDAQ:TXG) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 2.53% to the previous days close as strong demand from buyers drove the stock to $150.99. Actively observing the price movement in the last trading, the stock closed the session at $147.27, falling within a range of $141.81 10x Genomics Inc. (NASDAQ: TXG) Stock Could Be An Option To Consider Read More »

The

Green Alpha Advisors LLC raised its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 15.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,288 shares of the companys stock after buying an additional 863 shares during the period. Green Alpha Advisors LLCs holdings in []

10x Genomics, Inc. (NASDAQ:TXG) insider Bradford Crutchfield sold 17,000 shares of the companys stock in a transaction that occurred on Friday, November 12th. The shares were sold at an average price of $164.92, for a total transaction of $2,803,640.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be []

Prudential Financial Inc. increased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 3.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,178 shares of the companys stock after purchasing an additional 550 shares during the period. Prudential Financial []

In this GEN webinar, sponsored by 10X Genomics, our distinguished guest speaker Dr. Rui Chen will discuss how his team at Baylor College of Medicine took on the complexity of gene expression and regulation in the human retina by generating a multiomic cell atlas at single-cell resolution. The post Single Cell Multiomic Atlas of the Human Retina: An Integrative Analysis appeared first on GEN - Genetic Engineering and Biotechnology News .

Both companies offer disruptive new solutions in their niches of the healthcare space.

10x Genomics Inc (NASDAQ: TXG) reported Q3 sales of $125.3 million, beating the consensus of $122.62 million. Sales increased 74% Y/Y, primarily due to increased consumables revenue driven by growth

10x Genomics (TXG) delivered earnings and revenue surprises of 16.67% and 0.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.

The mean of analysts' price targets for 10x Genomics (TXG) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among anal

PLEASANTON, Calif., Oct. 7, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd,

10x Genomics (NASDAQ:TXG) shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and announced a $180 price target. 10x Genomics' stock is currently down 7.53% to a

PLEASANTON, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference

BIGZ: A Long-Term Income Investment With Some Growth Opportunity